Choroba tay-sachsa

Choroba tay-sachsa
Leczenie

Choroba Tay-Sachsa to rzadka, autosomalna recesywna choroba neurodegeneracyjna spowodowana deficytem enzymu heksozaminidazy A (HexA), prowadzącym do akumulacji gangliozydów GM2 w neuronach. Obecnie brak jest terapii przyczynowej, a leczenie jest objawowe i wielodyscyplinarne, obejmujące stosowanie leków przeciwpadaczkowych, antybiotyków, leków zmniejszających wydzielanie śliny oraz terapię fizjoterapeutyczną i logopedyczną. Kluczowe jest indywidualne dostosowanie terapii, w tym kontrola napadów drgawkowych, zapobieganie aspiracji i infekcjom dróg oddechowych, a także wsparcie psychologiczne dla pacjentów i rodzin. Fizjoterapia i terapia zajęciowa mają na celu utrzymanie funkcji motorycznych i poprawę jakości życia, natomiast w zaawansowanych stadiach stosuje się urządzenia wspomagające mobilność i karmienie (np. sondy nosowo-żołądkowe, gastrostomia PEG).

Wprowadzenie do leczenia choroby Tay-Sachsa

Choroba Tay-Sachsa to rzadkie, genetyczne schorzenie, charakteryzujące się postępującą neurodegeneracją spowodowaną brakiem enzymu heksozaminidazy A (HexA), który prowadzi do gromadzenia się gangliozydów GM2 w komórkach nerwowych. Aktualnie nie istnieje skuteczne leczenie przyczynowe ani sposoby spowolnienia progresji choroby Tay-Sachsa. Leczenie koncentruje się głównie na łagodzeniu objawów, zapobieganiu powikłaniom oraz zapewnieniu komfortu i wsparcia pacjentom¹². Warto zaznaczyć, że w standardowym postępowaniu terapeutycznym konieczne jest zaangażowanie wielodyscyplinarnego zespołu specjalistów, który zapewni kompleksową opiekę medyczną³.

Leczenie objawowe i podtrzymujące

Leczenie objawowe ma kluczowe znaczenie w poprawie jakości życia pacjentów z chorobą Tay-Sachsa i obejmuje różnorodne metody terapeutyczne dostosowane do indywidualnych potrzeb chorego¹².

Farmakoterapia

W leczeniu objawowym stosuje się szereg leków, które mają na celu łagodzenie objawów i zapobieganie powikłaniom¹. Do najczęściej stosowanych należą:

Leki przeciwpadaczkowe – kontrolujące napady drgawkowe, które często wymagają złożonej terapii wielolekowej i regularnego dostosowywania dawek ze względu na zmieniający się charakter napadów²³
Antybiotyki – stosowane w leczeniu infekcji, zwłaszcza dróg oddechowych¹
Leki zmniejszające wydzielanie śliny – pomagające zapobiegać aspiracji i gromadzeniu się wydzieliny w płucach¹
Leki przeciwdepresyjne i przeciwpsychotyczne – w przypadku późnej postaci choroby Tay-Sachsa, należy jednak zachować ostrożność przy stosowaniu trójpierścieniowych leków przeciwdepresyjnych, fenotiazyn, haloperidolu i risperidonu ze względu na możliwe działania niepożądane⁴

Fizjoterapia i terapia zajęciowa

Fizjoterapia odgrywa istotną rolę w utrzymaniu funkcji motorycznych i zapobieganiu powikłaniom⁵. Terapia obejmuje:

Ćwiczenia utrzymujące elastyczność stawów i zakres ruchów⁵
Techniki opóźniające sztywność stawów i ograniczające utratę funkcji⁶
Fizjoterapię klatki piersiowej (CPT) – pomagającą usuwać wydzielinę z płuc¹
Indywidualnie dostosowane programy terapii zajęciowej mające na celu poprawę funkcjonowania w codziennych czynnościach⁵⁷

W przypadku późnej postaci choroby Tay-Sachsa fizjoterapia koncentruje się na utrzymaniu niezależności i mobilności. Mogą być wówczas stosowane specjalistyczne urządzenia wspomagające poruszanie się, takie jak wózki inwalidzkie⁸.

Terapia mowy i języka

Terapeuci mowy i języka zapewniają wsparcie w zakresie problemów z połykaniem, które często występują w chorobie Tay-Sachsa⁵. Ich rola obejmuje:

Naukę technik bezpiecznego połykania⁹
Instruktaż dotyczący odpowiedniego pozycjonowania pacjenta w celu zmniejszenia ryzyka aspiracji i refluksu⁹
Wsparcie w zachowaniu odruchu ssania i połykania, szczególnie u niemowląt¹⁰

Wsparcie żywienia i oddychania

Pacjenci z chorobą Tay-Sachsa często mają problemy z przyjmowaniem pokarmów oraz trudności z oddychaniem⁵. Wsparcie w tym zakresie obejmuje:

Stosowanie urządzeń wspomagających karmienie, takich jak sondy nosowo-żołądkowe lub gastrostomia (PEG) w przypadku nasilonych trudności z połykaniem⁵¹¹
Techniki pozycjonowania w celu zmniejszenia ryzyka aspiracji i gromadzenia się wydzieliny¹
Fizjoterapię klatki piersiowej, ćwiczenia i inne techniki pomagające usuwać wydzielinę z płuc¹
Stosowanie specjalistycznych urządzeń, takich jak kamizelki wibracyjne, które pomagają usuwać wydzielinę z dróg oddechowych u pacjentów z ograniczoną kontrolą mięśni¹²

Wsparcie psychologiczne i opieka paliatywna

Ważnym elementem leczenia jest również wsparcie psychologiczne dla pacjentów i ich rodzin¹³. Obejmuje ono:

Poradnictwo rodzinne pomagające członkom rodziny radzić sobie z chorobą¹³
Grupy wsparcia dla rodzin dotkniętych chorobą Tay-Sachsa¹³
Opiekę paliatywną skupiającą się na zapewnieniu komfortu i poprawie jakości życia¹⁴
Wsparcie w zakresie decyzji dotyczących opieki u schyłku życia¹⁴

Eksperymentalne metody leczenia

Mimo braku zatwierdzonej terapii modyfikującej przebieg choroby, trwają intensywne badania nad różnymi strategiami leczenia, które mogłyby zapewnić skuteczne leczenie przyczynowe choroby Tay-Sachsa¹⁵.

Enzymatyczna terapia zastępcza (ERT)

Enzymatyczna terapia zastępcza polega na dostarczaniu syntetycznej lub zmodyfikowanej formy brakującego enzymu HexA¹⁶. Mimo obiecujących założeń, ERT w leczeniu choroby Tay-Sachsa napotyka na istotne wyzwania:

Bariera krew-mózg uniemożliwia większości cząsteczek, w tym enzymom, przenikanie do mózgu²
Skuteczna ERT w chorobie Tay-Sachsa wymaga syntezy zarówno podjednostki alfa, jak i beta enzymu HexA¹⁵¹⁷
Istnieją obiecujące wyniki badań z wykorzystaniem rekombinowanego białka chimerycznego, składającego się z HexA połączonego z elementami umożliwiającymi przejście przez barierę krew-mózg²

Terapia redukcji substratu (SRT)

Terapia redukcji substratu ma na celu hamowanie powstawania specyficznych substratów zmutowanego enzymu, co zmniejsza akumulację gangliozydów GM2 w komórkach¹⁸. W badaniach nad SRT:

Stosowano miglustat (N-butyldeoxynojirimycin) – inhibitor enzymu glukozyloceramidosyntetazy, który wykazał skuteczność na modelach mysich, ale nie u ludzi¹⁹²⁰
FDA nie zatwierdziła stosowania miglustatu w leczeniu choroby Tay-Sachsa¹⁹
Venglustat (GZ402671) – eksperymentalny lek z grupy SRT opracowany przez Genzyme, ukierunkowany na zmniejszenie akumulacji gangliozydów GM2 poprzez hamowanie glukozyloceramidosyntetazy²⁰

Terapia wspomagająca enzymy

Terapia wspomagająca enzymy wykorzystuje małe cząsteczki (chaperony) do stabilizacji enzymów i zwiększenia ich aktywności³:

Chaperony farmakologiczne mogą promować prawidłowe fałdowanie enzymu HexA w komórkach pacjentów¹⁵
Pirymidyna wykazała w badaniach 4-krotny wzrost poziomu HexA, jednak korzyści kliniczne nie zostały potwierdzone¹⁹²¹
Nowsze badania skupiają się na małych cząsteczkach, które działają jako chaperony bez efektu inhibicyjnego²²

Terapia genowa

Terapia genowa jest jedną z najbardziej obiecujących metod leczenia choroby Tay-Sachsa, ponieważ choroba jest spowodowana przez mutację pojedynczego genu²³. Ostatnie osiągnięcia w tej dziedzinie obejmują:

Wektory oparte na wirusie związanym z adenowirusem (AAV), dostarczające funkcjonalne kopie genu HEXA do komórek mózgu²³²⁴
Pierwsze próby kliniczne terapii genowej u dzieci z chorobą Tay-Sachsa, wykorzystujące dwa nieszkodliwe wektory wirusowe do dostarczenia instrukcji DNA do komórek mózgu²⁵²⁶
Wstępne wyniki wskazują na potencjalną stabilizację choroby i poprawę funkcji neurologicznych u leczonych dzieci²⁵²⁶
AXO-AAV-GM2 – eksperymentalna terapia genowa wykorzystująca kombinację wektorów AAVrh8-HEXA i AAVrh8-HEXB, która otrzymała zgodę FDA na badania kliniczne²⁷²⁸

W lutym 2022 roku ogłoszono pierwsze zastosowanie terapii genowej u dwojga dzieci z chorobą Tay-Sachsa, co stanowi przełom w leczeniu tego schorzenia²⁹. Pierwsze dziecko, które otrzymało terapię w wieku 2,5 roku, wykazywało lepszą kontrolę mięśni i zdolność skupienia wzroku trzy miesiące po leczeniu, a drugie dziecko leczone w wieku 7 miesięcy miało poprawiony rozwój mózgu i pozostaje wolne od napadów padaczkowych²⁶²⁵.

Terapia komórkowa i przeszczepy

Terapia komórkowa, w tym przeszczep szpiku kostnego i komórek macierzystych, jest badana jako potencjalna metoda leczenia choroby Tay-Sachsa¹⁸:

Hematopoetyczne przeszczepienie komórek macierzystych (HSCT) może być realizowane poprzez przeszczep komórek macierzystych z krwi obwodowej, szpiku kostnego lub krwi pępowinowej¹⁸
Przeszczep ex vivo zmodyfikowanych multipotencjalnych komórek neuronalnych z ekspresją ludzkiego genu HEXA jest badany jako alternatywna strategia terapeutyczna²³³⁰
Kalifornijski Instytut Medycyny Regeneracyjnej przyznał finansowanie na rozwój terapii genowej z wykorzystaniem komórek macierzystych krwi dla pacjentów z chorobą Tay-Sachsa³¹

Inne eksperymentalne podejścia

Trwają badania nad innymi potencjalnymi metodami leczenia choroby Tay-Sachsa:

Technologia antysensownych oligonukleotydów (ASO) jako dodatkowa strategia rozwoju terapeutycznego¹⁸
4-fenylokwas masłowy (4-PBA) – lek zatwierdzony przez FDA do stosowania w innym schorzeniu, który wykazał poprawę funkcji motorycznych, wydłużenie czasu przeżycia i zwiększenie liczby zdrowych neuronów ruchowych w modelu mysim³²
Technika edycji genów CRISPR, badana przez Hospital for Sick Children w Kanadzie³³

Kompleksowa opieka nad pacjentem

Opieka nad pacjentem z chorobą Tay-Sachsa wymaga zaangażowania wielodyscyplinarnego zespołu specjalistów, który zapewni kompleksową opiekę medyczną i wsparcie³³⁴.

Zespół specjalistów

W skład zespołu opieki nad pacjentem z chorobą Tay-Sachsa mogą wchodzić:

Neurolodzy dziecięcy – pomagający w diagnozie i leczeniu objawów neurologicznych³¹⁰
Genetycy medyczni – zajmujący się diagnostyką i poradnictwem genetycznym³
Pediatrzy i pulmonolodzy – pomagający w zapobieganiu infekcjom płuc i problemom oddechowym¹⁰
Fizjoterapeuci i terapeuci zajęciowi – wspierający funkcje motoryczne i zdolności adaptacyjne⁵
Logopedzi – pomagający w problemach z połykaniem i karmieniem⁵
Specjaliści żywienia – zapewniający odpowiednie wsparcie żywieniowe³⁵
Specjaliści opieki paliatywnej – pomagający w zapewnieniu komfortu i poprawie jakości życia¹¹

Podejście indywidualne

Każdy pacjent z chorobą Tay-Sachsa wymaga indywidualnego podejścia terapeutycznego, dostosowanego do jego specyficznych potrzeb i objawów³⁴⁷. Ważne jest regularne monitorowanie stanu pacjenta i dostosowywanie planu leczenia do zmieniających się potrzeb, szczególnie w przypadku napadów padaczkowych, które mogą zmieniać swój wzorzec i wymagać częstych zmian dawek leków².

Wsparcie dla rodzin

Istotnym elementem opieki nad pacjentem z chorobą Tay-Sachsa jest wsparcie psychologiczne i praktyczne dla rodzin¹³. Wsparcie to może obejmować:

Poradnictwo genetyczne dla rodzin³⁶
Grupy wsparcia i organizacje pacjenckie, takie jak National Tay-Sachs & Allied Diseases Association (NTSAD)³⁷
Edukację na temat choroby, jej przebiegu i dostępnych opcji terapeutycznych³⁷
Wsparcie w zakresie opieki wytchnieniowej i dostępu do usług opiekuńczych³⁸

Przyszłość leczenia choroby Tay-Sachsa

Intensywne badania naukowe nad nowymi metodami leczenia choroby Tay-Sachsa dają nadzieję na przyszłość. Obecnie najbardziej obiecujące kierunki badań obejmują¹⁶:

Terapię genową, która wykazała już wstępną skuteczność w badaniach klinicznych²⁵²⁶
Enzymatyczną terapię zastępczą z wykorzystaniem nowych metod dostarczania enzymu do mózgu²
Przeszczepianie genetycznie zmodyfikowanych komórek macierzystych³¹
Kombinację różnych podejść terapeutycznych, które mogłyby synergistycznie poprawić wyniki leczenia²³

Warto podkreślić, że wczesne rozpoczęcie leczenia, zanim dojdzie do nieodwracalnych uszkodzeń neurologicznych, może mieć kluczowe znaczenie dla skuteczności przyszłych terapii²³. Badania kliniczne nad terapią genową kontynuują testowanie wyższych dawek w większej liczbie pacjentów, co może przynieść lepsze wyniki terapeutyczne³⁹.

Podsumowanie

Mimo braku skutecznego leczenia przyczynowego choroba Tay-Sachsa pozostaje przedmiotem intensywnych badań naukowych, które dają nadzieję na przyszłość. Obecnie leczenie koncentruje się głównie na łagodzeniu objawów i zapewnieniu komfortu pacjentom, jednak postępy w dziedzinie terapii genowej, enzymatycznej terapii zastępczej i innych innowacyjnych podejść mogą w przyszłości doprowadzić do opracowania skutecznych metod leczenia tej wyniszczającej choroby⁵¹⁸.

Kompleksowa opieka nad pacjentem z chorobą Tay-Sachsa wymaga zaangażowania wielodyscyplinarnego zespołu specjalistów oraz indywidualnego podejścia terapeutycznego, dostosowanego do specyficznych potrzeb każdego pacjenta. Wsparcie psychologiczne i praktyczne dla rodzin stanowi istotny element opieki nad chorymi z tym rzadkim schorzeniem genetycznym³¹³.

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 Tay-Sachs disease | UM Health-Sparrow
https://www.uofmhealthsparrow.org/departments-conditions/conditions/tay-sachs-disease
There is no cure for Tay-Sachs disease, and no treatments are currently proved to slow progression of the disease. Some treatments can help in managing symptoms and preventing complications. The goal of treatment is support and comfort. […] Supportive treatments include: […] A number of prescription medications are available to reduce symptoms and prevent complications: for example, anti-seizure medications or antibiotics for infection. […] Accumulated mucus in the lungs is common and results in a high risk of lung infections that cause breathing problems. Chest physiotherapy (CPT), exercise and other techniques can help remove mucus from the lungs. Medications to reduce saliva production and positioning techniques are also options to reduce the risk of mucus accumulation and prevent aspiration pneumonia.
#2 Tay-Sachs Disease – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK564432/
Treatment of Tay-Sachs disease is largely supportive with the goals of providing adequate nutrition, controlling seizures, managing the infectious sequelae, protecting the airway, and early aggressive physical and occupational therapy. Seizure control usually requires multiple antiepileptics. However, seizures become progressive and change in pattern, so frequent dose changes and initiating new medications are essential. As the child with Tay-Sachs disease becomes more disabled and debilitated, good bowel management becomes essential. Therapeutic modalities for Tay-Sachs disease include enzyme replacement therapy, cell transplantation, substrate reduction therapy, enzyme enhancing therapy, and gene therapy. […] Enzyme replacement therapy is a promising option for Tay-Sachs disease. Currently, enzyme replacement therapy is less effective in Tay-Sachs disease due to the inability to cross the blood-brain barrier and prevent neurological complications. Results in a recent encouraging report showed that using a recombinant chimeric protein composed of Hex A linked to 2 blood-brain barrier entry elements (dual trojan horse protein), a transferrin receptor binding sequence, and a granulocyte-colony stimulating factor yielded good outcomes.
#3 Tay-Sachs disease – Care at Mayo Clinic – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/tay-sachs-disease/care-at-mayo-clinic/mac-20378198
Mayo Clinic specialists provide compassionate care for children who have Tay-Sachs disease, and take the time to address the family’s concerns and questions. […] Teams of experts work together to personalize your child’s care and offer support for your family. […] Mayo Clinic experts trained in pediatric neurology, pediatric rehabilitation, genetic disorders (medical geneticists) and other specialties work together to treat children who have Tay-Sachs disease. […] Your Mayo Clinic care team will provide treatment and follow-up care for your child and will coordinate the treatment and support plan with your child’s primary care provider or pediatrician. […] Mayo Clinic offers sophisticated diagnostic testing in children and genetic screening in parents for Tay-Sachs disease. […] Mayo Clinic respiratory therapists have extensive experience in providing therapies, such as CPT, to children with Tay-Sachs disease.
#3 Tay-Sachs Disease: Treatments, Symptoms, Risks, and More
https://www.healthline.com/health/neurological-health/tay-sachs-disease
At present, theres no cure for Tay-Sachs disease. Typically, treatment is supportive, focused on reducing symptoms and improving quality of life. This is also known as palliative care. […] Treatments may include: medication for pain, anti-epileptic medication to control seizures, physical therapy, nutritional support, respiratory treatment. […] Research is ongoing for more effective treatments for Tay-Sachs disease. Several options have shown some benefits in animals, but have had limited results in people. Potential treatments include: Enzyme replacement therapy. Since Tay-Sachs is caused by the lack of the Hex-A enzyme, this treatment seeks to replace the enzyme. So far, several complications have kept this from being effective for Tay-Sachs. […] Enzyme-enhancing therapy. This therapy uses molecules to stabilize enzymes and increase their activity. More research is needed on this treatment.
#4 TayâSachs disease – Wikipedia
https://en.wikipedia.org/wiki/Tay%E2%80%93Sachs_disease
The treatment of TaySachs disease is supportive in nature. This may involve multiple specialties as well as psychosocial support for the family. […] Researchers are looking at gene therapy or enzyme replacement therapy as possible treatments. […] As of 2010, no treatment addressed the cause of TaySachs disease or could slow its progression; people receive supportive care to ease the symptoms and extend life by reducing the chance of contracting infections. […] In late-onset TaySachs, medication (e.g., lithium for depression) can sometimes control psychiatric symptoms and seizures, although some medications (e.g., tricyclic antidepressants, phenothiazines, haloperidol, and risperidone) are associated with significant adverse effects. […] Enzyme replacement therapy techniques have been investigated for lysosomal storage disorders, and could potentially be used to treat TaySachs as well.
#5 Tay-Sachs disease | UM Health-Sparrow
https://www.uofmhealthsparrow.org/departments-conditions/conditions/tay-sachs-disease
Your child may have trouble swallowing or develop respiratory problems by inhaling food or liquid into the lungs while eating. To prevent those problems, your doctor may recommend an assistive feeding device such as a feeding tube. A feeding tube may be inserted through your child’s nose and into the stomach, or a surgeon may surgically insert a feeding tube directly into the stomach (gastrostomy tube). […] As the disease progresses, your child may benefit from physical therapy to help keep joints flexible and maintain as much ability to move (range of motion) as possible. Physical therapy may delay joint stiffness and reduce or delay the loss of function and pain that can result from affected muscles. […] These therapists can recommend activities and supportive devices to help with daily functioning. […] Speech and language therapists can assist with swallowing problems. […] Research on treatments such as gene therapy, stem cell transplantation, or enzyme replacement therapy may eventually lead to a cure or treatment to slow the progression of Tay-Sachs disease.
#6 Tay-Sachs disease – Augusta HealthSearchClose SearchSearch IconSearch IconClose Search IconMobile Menu IconMobile Menu Close IconInstagramFacebookTwitterYoutube
https://www.augustahealth.com/disease/tay-sachs-disease/
Nutrition and hydration. Your child may have trouble swallowing or develop respiratory problems by inhaling food or liquid into the lungs while eating. To prevent those problems, your doctor may recommend an assistive feeding device such as a feeding tube. A feeding tube may be inserted through your child’s nose and into the stomach, or a surgeon may surgically insert a feeding tube directly into the stomach (gastrostomy tube). […] Physical therapy. As the disease progresses, your child may benefit from physical therapy to help keep joints flexible and maintain as much ability to move (range of motion) as possible. Physical therapy may delay joint stiffness and reduce or delay the loss of function and pain that can result from affected muscles. […] Occupational therapy. These therapists can recommend activities and supportive devices to help with daily functioning. […] Speech and language therapy. Speech and language therapists can assist with swallowing problems. […] Research on treatments such as gene therapy, stem cell transplantation, or enzyme replacement therapy may eventually lead to a cure or treatment to slow the progression of Tay-Sachs disease.
#7 Late Onset Tay-Sachs Disease
https://www.physio.co.uk/what-we-treat/neurological/conditions/late-onset-tay-sachs-disease.php
Physiotherapy plays an important part in helping individuals with this condition manage their physical symptoms and improve their independence with daily activities. Physiotherapy treatment will depend on your current symptoms and needs. […] At Physio.co.uk we provide specialised and individualised physiotherapy treatment for people with Late Onset Tay-Sachs. […] Physiotherapy treatment at Physio.co.uk will focus on: […] Every person with this condition is different so treatment will be tailored to your particular needs. Physiotherapy treatment may include: […] Our physiotherapists at Physio.co.uk work closely with occupational therapists who can provide adjustments or equipment in the kitchen, bathroom or workspace.
#8 Tay-Sachs Disease: What It Is, Causes, Symptoms & Treatment
https://my.clevelandclinic.org/health/diseases/14348-tay-sachs-disease
Treatment for Tay-Sachs disease is supportive of your childs symptoms. For example, your healthcare provider may prescribe medication to manage seizures. Other treatment measures include providing proper nutrition and hydration. Your childs provider will make them as comfortable as possible. […] Treatment is available to help adults diagnosed with Tay-Sachs disease manage their symptoms, including: Using assistive devices or mobility equipment (wheelchair) to help with independence and navigation. Taking medication to manage mental health conditions or muscle spasms. Speech therapy. […] No, there isnt a cure available for Tay-Sachs disease.
#9 Infantile Tay-Sachs Disease – NTSAD
https://ntsad.org/diseases/tay-sachs-disease/infantile-tay-sachs-disease/
Healthcare providers are always welcome to consult with our Family Services Team about specific issues so they can care for children with infantile Tay-Sachs disease. […] There is currently no cure for Tay-Sachs disease, but there are treatments to help manage symptoms and maintain a baseline for as long as possible. […] While there is currently no cure for infantile Tay-Sachs disease, it is possible to manage symptoms like seizures and trouble swallowing as guided by your Philosophy of Care. […] We recommend that you develop a respiratory health management plan with your pediatrician and consult with a pulmonologist for advanced respiratory health needs and management. […] A trusted neurologist will help you manage seizures and develop a seizure management plan. […] A speech language pathologist can provide techniques to promote the suck-swallow reflex and can show you proper positioning techniques to reduce the risk of aspiration pneumonia and reflux. […] Complementary therapies can be used alongside traditional medicine to provide comfort and relaxation.
#10 Tay-Sachs Disease: Symptoms, Causes, Treatment, Prevention
https://www.webmd.com/parenting/baby/what-is-tay-sachs-disease
Researchers are working to make advances in gene therapy or bone marrow transplants that they hope will allow treatment of Tay-Sachs in the future […] Some of the specialists, treatments, and programs you might consider include: […] Speech-language pathologists. They can provide ways to help your baby keep the suck-swallow reflex going as well as help you figure out when it is time to consider a feeding tube for your little one. […] Neurologists. These specialists can help you manage your babys seizures with medication. […] Respiratory health. Specialists such as pediatricians and pulmonologists (doctors who treat lung and breathing problems) can recommend ways for parents to lower their childs chance of lung infections. […] Chest physiotherapy (CPT). Therapy to tap on the chest wall can help break up mucus in the lungs so your child can cough it up.
#11 Tay-Sachs Disease: Symptoms, Causes, Treatment, Prevention
https://www.webmd.com/parenting/baby/what-is-tay-sachs-disease
Feeding tubes. Your child may have trouble swallowing or may have breathing problems that include inhaling food or liquid into their lungs while eating. You can insert a feeding tube through your childs nose into their stomach each time. A doctor may also put a tube in a tube during surgery. […] Play and stimulation. You can help your child interact with the world through music, scents, and textures. […] Massages. These can relax your baby. […] Palliative and hospice care. These programs help manage the quality of life for children with Tay-Sachs and their families.
#12 Parents spark breakthrough gene therapy for children with Tay-Sachs disease | The Independent
https://www.independent.co.uk/news/world/americas/taysachs-gene-therapy-b2017038.html
For more than a century there has been no cure, no treatment and no hope for children diagnosed with Tay-Sachs disease. […] But Siena is still alive, thanks in part to a new gene therapy that could revolutionise the treatment of Tay-Sachs. […] Other gene therapy programmes are also under way, raising the possibility that soon, for the first time in history, children diagnosed with Tay-Sachs might grow up to live long and full lives. […] Some palliative treatments are now available, such as cannabinoid-based anti-seizure drugs and a vibrating „shake vest” that dislodges fluid in the wearer’s lungs or throat once they become unable to control the relevant muscles. […] The research was promising enough it has now been licensed by Sio Gene Therapies, a clinical trial company focused entirely on neurodegenerative diseases, which is conducting further trials with more patients and stronger doses.
#13 Tay-Sachs Disease Information & Treatment
https://www.columbiadoctors.org/health-library/condition/tay-sachs-disease/
The focus of treatment for Tay-Sachs disease is to control symptoms and make your child as comfortable as possible. There is no cure. It may be helpful to seek counseling or find support from others who are going through the same thing you are. […] If you have late-onset Tay-Sachs disease (LOTS), treatment also focuses on controlling symptoms. The treatment you receive, such as medicine for depression, depends on the symptoms you have. […] Talk to your doctor about: […] A support group in your area. […] Family counseling to help each member cope with the disease. […] As the disease gets worse, your child will need more care. Encourage your child to be as active as possible for as long as possible. Give your child your love and affection. […] You may not be able to care for your child without help. Talk with your doctor about groups that can help you.
#14 Tay-Sachs disease
https://www.nhs.uk/conditions/tay-sachs-disease/
There’s currently no cure for Tay-Sachs disease. The aim of treatment is to make living with it as comfortable as possible. […] You’ll see a team of specialists, who will help come up with a treatment plan for your child. […] Treatments may include: medicines for seizures and stiffness, speech and language therapy for feeding and swallowing problems sometimes special bottles or a feeding tube may be needed, physiotherapy to help with stiffness and improve coughing (to reduce the risk of pneumonia), antibiotics to treat infections like pneumonia if they occur. […] Your care team will talk to you about end of life care, such as where you’d like your child to receive care and if you’d like them to be resuscitated if their lungs stop working.
#15 Therapeutic Strategies For Tay-Sachs Disease
https://pmc.ncbi.nlm.nih.gov/articles/PMC9294361/
Tay-Sachs disease (TSD) is an autosomal recessive disease that features progressive neurodegenerative presentations. It affects one in 100,000 live births. Currently, there is no approved therapy or cure. This review summarizes multiple drug development strategies for TSD, including enzyme replacement therapy, pharmaceutical chaperone therapy, substrate reduction therapy, gene therapy, and hematopoietic stem cell replacement therapy. […] For TSD, ERT remains challenging because a successful ERT must comprise of both a functional alpha and beta subunit of HexA. Several groups have developed functional HexA enzyme which have alleviated disease phenotypes in vitro. […] For TSD, some mutations cause misfolded HexA enzymes that are degraded quickly before the enzyme can move to the lysosome. One potential solution for these misfolded HexA enzymes is the use of pharmacological chaperones to promote proper folding in patient cells.
#16 The Future of Tay-Sachs: Advancements in Research and Therapy – Cure Tay-Sachs
https://www.curetay-sachs.org/the-future-of-tay-sachs-advancements-in-research-and-therapy/
The future of Tay-Sachs disease holds potential as researchers and medical professionals tirelessly work towards groundbreaking advancements in research and therapy. […] Pioneering research is essential to unlocking new possibilities for treatment and ultimately finding a cure for Tay-Sachs disease. […] One of the most significant advancements in recent years for Tay-Sachs disease has been gene therapy. […] Another promising research avenue is enzyme replacement therapy (ERT), which involves delivering synthetic or modified enzymes to compensate for the deficiency in hexosaminidase A. […] While groundbreaking therapies like gene and enzyme replacement therapy hold promise, supportive therapies, and symptom management remain crucial for improving the quality of life for individuals with Tay-Sachs disease. […] The future of Tay-Sachs disease is evolving with advancements in gene therapy, enzyme replacement, and supportive therapies offering hope for better outcomes and quality of life.
#17 New Approaches to Tay-Sachs Disease Therapy – Blu Genes Foundation
https://blugenes.org/blugenes-news-updates/blu-genes-foundation-impact-research-and-news/new-approaches-to-tay-sachs-disease-therapy-2/
Currently, Tay-Sachs disease treatment is based on symptom relief and, in case of the late-onset form, on the delay of progression. […] There are also clinical reports of substrate reduction therapy using miglustat and bone marrow or hematopoietic stem cell transplantation. […] The development of enzyme replacement therapy (ERT) is a promising option for the treatment of lysosomal storage diseases. […] The major challenge in creating HexA-based ERT is the need to synthesize both of the enzyme subunits. […] Jacobs et al. (2005) published the clinical case of the application of bone marrow transplantation (BMT) with the following substrate reduction therapy to treat the patient with TSD. […] An alternative approach for patients who do not have a suitable bone marrow donor is transplantation of hematopoietic stem cells from umbilical cord blood obtained from partially HLA-matched unrelated donors.
#18 Therapeutic Strategies For Tay-Sachs Disease
https://pmc.ncbi.nlm.nih.gov/articles/PMC9294361/
Substrate reduction therapy (SRT) is a therapeutic strategy to inhibit the formation of specific substrates of a mutant enzyme that reduces the need of this enzyme to hydrolyze its substrate, resulting in a decrease in the substrate accumulation of the lysosomal storage disease. […] HSCT is mainly achieved through transplantation of stem cells from peripheral blood, bone marrow, or umbilical cord blood. […] Gene therapy utilizes viral vectors for the delivery of a functional gene to correct a genetic defect. Since TSD defects are monogenic, gene therapy is a promising treatment for this disease. […] Recent developments in antisense oligonucleotide (ASO) technology provides additional therapeutic development strategy.
#19 Tay-Sachs Disease – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK564432/
Most mutations causing Tay-Sachs disease are not localized to the active site but often cause instability of native folded protein. Strategies to reduce the substrate include using molecules called chaperones to stabilize the enzyme. Interestingly, the pharmacological chaperones used are enzyme-specific competitive inhibitors. A trial of the Hex A inhibitor pyrimethamine demonstrated 4-fold increases in Hex A levels, but clinical benefits are not reported. […] The rationale behind substrate reduction therapy is balancing substrate synthesis with diminished enzyme degradative power. The substrate-reduction drug miglustat (N-butyldeoxynojirimycin) has succeeded in mouse models but not humans. Currently, the US Food and Drug Administration has not approved the use of miglustat in treating Tay-Sachs disease.
#20 Tay Sachs Disease Pipeline Insight Analysis Report: Recent
https://www.globenewswire.com/news-release/2025/03/17/3043846/28124/en/Tay-Sachs-Disease-Pipeline-Insight-Analysis-Report-Recent-Advancements-Focus-on-Targeted-Therapies-and-Personalized-Medicine-to-Improve-Patient-Outcomes.html
Venglustat (GZ402671): Venglustat is an investigational substrate reduction therapy aimed at reducing the accumulation of GM2 ganglioside. Developed by Genzyme, it targets the underlying cause of Tay-Sachs by inhibiting glucosylceramide synthase. […] IB1001: IB1001 is a gene therapy candidate designed to deliver a functional HEXA gene to patients, thereby restoring hexosaminidase A enzyme activity and preventing GM2 ganglioside buildup.
#21 Azthena logo with the word Azthena
https://www.news-medical.net/health/Tay-Sachs-Disease-Research.aspx
Another approach that has been studied for the treatment of Tay-Sachs disease has been to increase the activity of the HEXA enzyme so that the deficiency that characterizes this disease is less significant. […] Pyrimethamine is a drug that has shown some activity in this area. Unfortuantely, the overall efficacy of this drug is not high, as the activity of -hexosaminidase A is still much lower than in unaffected populations.
#22 A Comprehensive Review on Treatment Strategies of Tay Sachs Disease
https://www.ijpsjournal.com/article/A+Comprehensive+Review+on+Treatment+Strategies+of+Tay+Sachs+Disease
Miglustat is another compound under investigation for its potential role in treating TSD. It functions as a competitive inhibitor of the glucosylceramide synthase enzyme, which is crucial for the synthesis of GM2 gangliosides. […] In recent years, gene therapy has emerged as one of the most significant advancements in the treatment of Tay-Sachs disease (TSD). […] The primary goal of gene therapy for Tay-Sachs disease is to correct the genetic mutation responsible for the absence of the HEXA enzyme. […] Pharmacological chaperones can promote proper folding of enzymes. One such compound, pyrimethamine (PYR), has been shown to inhibit HexA degradation long enough for the enzyme to complete its journey to the lysosome and sustain GM2 hydrolysis in vitro. […] While PYR is approved for treating toxoplasmosis and has been tested in TSD clinical trials, the outcomes were limited.
#23 Tay-Sachs Disease – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK564432/
Since a single disorder causes Tay-Sachs disease, gene therapy is an excellent therapeutic option. Significant progress has been made in developing adeno-associated virus-based vectors. The major limitation of adeno-based vectors is their capacity to carry constructs. For clinically significant therapy, a vector should carry Hex A isoenzyme, which should carry alpha and beta subunits. […] Another breakthrough approach involves transplanting ex vivo modified multipotent neural cells with human HEXA expression produced by retroviral transduction. Overall, adequate production and distribution of Hex A are required for a better therapeutic effect in Tay-Sachs disease. So far, substrate reduction therapy, bone marrow transplantation, and enzyme replacement therapy have shown low efficacy in preventing neurodegeneration. Hence, a combination of multiple therapies at an early age is essential since myelination defects appear early and worsen with time.
#24 Gene Therapy for Tay-Sachs Disease – Horae Gene Therapy Center
https://www.umassmed.edu/gtc/our-research/tay-sachs-disease/
Dr. Miguel Sena-Esteves from the Esteves Lab (Horae Gene Therapy Center) is conducting research and developing therapeutic strategies for rare inherited diseases such as the Tay-Sachs disease […] Dr. Sena-Esteves leads the Tay-Sachs Gene Therapy Consortium with the focus to develop an AAV gene therapy and conduct the first-in-human clinical trial. […] Currently, the Sena-Esteves Lab is working on devising new ways to deliver therapeutic levels of the missing enzyme Hexosaminidase A (HexA) to the entire brain by injection of adeno-associated virus (AAV) vectors into specific structures in the central nervous system. […] Dr. Sena-Esteves has devised new ways to deliver therapeutic levels of the missing enzymes to the entire brain by injection of adeno-associated virus (AAV) vectors into specific structures in the Central Nervous System (CNS). Based on the exceptional results that he and his lab members have obtained in animal models and pre-clinical studies they hope to soon move on to a human clinical trial for Tay-Sachs disease.
#25 First gene therapy for Tay-Sachs disease successfully given to two children
https://theconversation.com/first-gene-therapy-for-tay-sachs-disease-successfully-given-to-two-children-176870
Two babies have received the first-ever gene therapy for Tay-Sachs disease after over 14 years of development. […] Unfortunately there is still no treatment for Tay-Sachs. Aggressive medical treatment can extend survival but doesn’t improve neurological function. The only effective way to treat Tay-Sachs is to restore the HexA enzyme in the brain. This is difficult, however, because the blood-brain barrier prevents most molecules from passing into the brain. […] Our treatment uses two harmless viral vectors to deliver DNA instructions to brain cells that teach them how to produce the missing enzyme. […] The first child who received our gene therapy treatment was age 2, with late-stage disease symptoms. Three months after treatment, they had better muscle control and could focus their eyes. Now at age 5, the child is in stable health and is seizure-free, which usually isn’t possible for patients at this age. A second child treated at age 7 months had improved brain development by the three-month follow-up and remains seizure-free at a little over age 2.
#26 First gene therapy for Tay-Sachs disease successfully given to two children
https://www.umassmed.edu/news/news-archives/2022/02/first-gene-therapy-for-tay-sachs-disease-successfully-given-to-two-children/
Two babies have received the first-ever gene therapy for Tay-Sachs disease after over 14 years of development. […] Unfortunately there is still no treatment for Tay-Sachs. Aggressive medical treatment can extend survival but doesn’t improve neurological function. The only effective way to treat Tay-Sachs is to restore the HexA enzyme in the brain. […] Our treatment uses two harmless viral vectors to deliver DNA instructions to brain cells that teach them how to produce the missing enzyme. […] The first child who received our gene therapy treatment was age 2 1/2 half, with late-stage disease symptoms. Three months after treatment, they had better muscle control and could focus their eyes. […] A second child treated at age 7 months had improved brain development by the three-month follow-up and remains seizure-free at a little over age two. […] More testing is needed to confirm whether our treatment can fully stop disease progression. […] My colleagues and I are currently conducting a follow-up clinical trial to test the safety and efficacy of increasing doses in a larger number of patients.
#27 First Potential Gene Therapy for Tay-Sachs Disease Produces Positive Results at Three Month Mark â Patient Worthy
https://patientworthy.com/2019/03/13/first-potential-gene-therapy-tay-sachs-disease-produces-positive-results-three-month-mark/
The therapy they are investigating is called AXO-AAV-GM2. GM2 refers to GM2 gangliosidosis, otherwise known as Sandhoff disease and Tay-Sachs disease. This gene therapy works to provide patients a functioning copy of their impaired genes by using two AAVrh8 vectors. […] The latest update from this study was at the three-month mark. A 30-month-old patient diagnosed with Tay-Sachs disease was given a 1.0x 10^14 vg dose of the gene therapy into both the lumbar spinal canal and the cisterna magna. Researchers expect that patients who have less advanced stages of the disease who participate in this study later on will be able to additionally receive the therapy into the thalamus. […] No serious AEs reported. The therapy was generally well-tolerated. No laboratory abnormalities. The participant was in stable clinical condition. Enzyme activity within the cerebrospinal fluid increased from .46% of normal to 1.44% of normal. Activity of HEXA was increased at each and every time point. […] Further evaluation is still certainly needed, but these preliminary results are exciting for this patient population with a high unmet need.
#28
https://practicalneurology.com/news/fda-clears-ind-application-of-gene-therapy-for-tay-sachs-and-sandhoff-diseases/2469420/
The Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a registrational study of adeno-associated viral (AAV) vector gene therapy (AXO-AAV-GM2; Axovant Gene Therapies, New York, NY) to treat individuals with Tay-Sachs disease and Sandhoff disease. This therapy, if effective, will produce the enzyme beta-hexosaminidase A and B, deficiencies of which are causative for Tay Sachs syndrome and Sandhoff disease. It is hoped to be curative for both illnesses, which are lysosomal storage disorders, typically fatal in childhood. […] In 2019, clinical evidence from 2 participants under an investigator-initiated study found that treatment with the gene therapy was generally well-tolerated and associated with improved bioactivity outcomes. In addition, the data demonstrated the attainment of normal neurodevelopmental milestones and improvement in myelination. The gene therapy has been granted Orphan Drug and Rare Pediatric Disease Designation by the FDA.
#29 TayâSachs disease – Wikipedia
https://en.wikipedia.org/wiki/Tay%E2%80%93Sachs_disease
Researchers have also tried directly instilling the deficient enzyme hexosaminidase A into the cerebrospinal fluid (CSF) which bathes the brain. […] Other experimental methods being researched involve substrate reduction therapy, which attempts to use alternative enzymes to increase the brain’s catabolism of GM2 gangliosides to a point where residual degradative activity is sufficient to prevent substrate accumulation. […] Another metabolic therapy under investigation for TaySachs disease uses miglustat. […] As TaySachs disease is a deficiency of -hexosaminidase A, deterioration of affected individuals could be slowed or stopped through the use of a substance that increases its activity. […] This is a highly invasive procedure that involves destroying the patient’s blood system with chemotherapy and administering cord blood. […] On 10 February 2022, the first-ever gene therapy was announced, it uses an adeno-associated virus (AAV) to deliver the correct instruction for the HEXA gene on brain cells which causes the disease.
#30 New Approaches to Tay-Sachs Disease Therapy – Blu Genes Foundation
https://blugenes.org/blugenes-news-updates/blu-genes-foundation-impact-research-and-news/new-approaches-to-tay-sachs-disease-therapy-2/
Attempts to correct mutations in HEXA gene by gene and cell engineering began in the mid-1990s. […] The possibility of cross-correction to restore the metabolism of gangliosides in TSD patient-derived fibroblasts in vitro has been investigated. […] The major challenges in TSD gene therapy are the choice of the vector and delivery method of therapeutic genes in order to overcome the blood-brain barrier along with minimal side effects. […] Great progress has been achieved in developing approaches for GM2 gangliosidoses gene therapy using adeno-associated virus (AAV)-based vectors. […] The therapeutic efficacy of AAVrh8-based gene therapy on the Jacob sheep TSD model has been studied. […] The transplantation of ex vivo modified multipotent neural cells (MNCs) in the CNS is another therapeutic strategy.
#31 Finding a treatment for Tay-Sachs disease | The Stem Cellar
https://blog.cirm.ca.gov/2022/12/22/finding-a-treatment-for-tay-sachs-disease/
The California Institute for Regenerative Medicine (CIRM) has awarded $4,048,253 to Dr. Joseph Anderson and his team at UC Davis to develop a blood stem cell gene therapy for the treatment of Tay-Sachs disease. […] The UC Davis team will genetically modify the patients own blood stem cells to restore the Hex A enzyme that is missing in the disease. […] The goal is to complete safety studies and to apply to the US Food and Drug Administration for an Investigational New Drug (IND), the authorization needed to begin a clinical trial in people. […] The successful development of this therapy will not only help patients with Tay-Sachs but will demonstrate the use case of this therapeutic approach for other monogenic neurodegenerative diseases, the UC Davis team said.
#32 Azthena logo with the word Azthena
https://www.news-medical.net/news/20241114/Study-identifies-a-potential-treatment-for-Sandhoff-and-Tay-Sachs-diseases.aspx
In a groundbreaking study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs diseases two rare, often fatal lysosomal storage disorders that cause progressive damage to nerve cells in the brain and spinal cord. […] After years of investigating the diseases’ underlying mechanisms, the research team has identified an existing FDA-approved drug that could significantly improve quality of life for affected patients and their families. […] This breakthrough led to the identification of a potential therapeutic compound: 4-phenylbutyric acid (4-PBA), an FDA-approved drug initially developed for another condition. […] Testing in a mouse model of the disease showed that 4-PBA significantly improved motor function, extended lifespan, and increased the number of healthy motor neurons. […] „Offering an FDA-approved drug for off-label use could provide hope and improve both life expectancy and quality of life for these patients.” […] Further research is underway to identify the optimal human dosage of 4-PBA.
#33 Parents spark breakthrough gene therapy for children with Tay-Sachs disease | The Independent
https://www.independent.co.uk/news/world/americas/taysachs-gene-therapy-b2017038.html
There are other projects too, such as a gene therapy technique using the game-changing CRISPR gene editing technology that Blu Genes is funding at the Hospital for Sick Children in Canada. […] „With Siena the goal was never to cure,” says Ms Margani. „I think we knew that wouldn’t be possible with someone whose disease is so advanced as hers. The talk was more about stabilising disease, improving symptoms. In that context, the therapy certainly has achieved that for Siena.” […] The good news is that even a small change to patients fortunes could transform lives. […] When therapy becomes available for Tay Sachs and Sandhoff, discovering the diseases as early as possible will be essential.
#34 Tay-Sachs disease – Care at Mayo Clinic – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/tay-sachs-disease/care-at-mayo-clinic/mac-20378198
Mayo Clinic’s experienced specialists from many disciplines, including pediatric neurology, genetics and physical medicine and rehabilitation work together to treat children with Tay-Sachs disease and other rare neurological diseases. […] Every year, Mayo Clinic’s experts diagnose and care for children who have Tay-Sachs disease and offer support to their families. […] Highly skilled pediatric experts diagnose and treat all types of conditions in children. As a team, we work together to find answers, set goals and develop a treatment plan tailored to your child’s needs.
#35 Tay-Sachs disease – symptoms, causes, diagnosis & treatment | healthdirect
https://www.healthdirect.gov.au/tay-sachs-disease
There is currently no cure or effective treatment for Tay-Sachs disease. […] but your health team can offer palliative care options to ease symptoms. This may include nutritional support and medicines to treat seizures. […] Psychological support is recommended for the whole family.
#36 Tay-Sachs Disease
https://lakecountyin.gov/departments/health/Nursing-Clinic/Diseases-and-Conditions/Genetic-Disorders/tay-sachs-disease
Currently, there is no cure for Tay-Sachs Disease, and treatment focuses on managing symptoms and providing supportive care: […] Symptomatic Treatment: – Seizure Management: Medications to control seizures and reduce their frequency. – Supportive Care: Interventions to manage motor symptoms, such as physical therapy and occupational therapy. […] Nutritional Support: – Feeding Assistance: Nutritional support and feeding assistance to address difficulties with swallowing and maintain adequate nutrition. […] Palliative Care: – Comfort and Quality of Life: Focus on providing comfort and improving the quality of life for affected individuals and their families. […] Genetic Counseling: – Family Support: Counseling for families to understand the genetic aspects of the disease, discuss reproductive options, and explore potential participation in clinical trials. […] While there is currently no cure, early diagnosis, symptomatic treatment, and supportive care play crucial roles in managing the disease and improving the lives of affected individuals and their families.
#37 Tay-Sachs Disease Services, Resources & Support: A Comprehensive Guide | Disability Resources
https://www.disabilityresources.org/tay.html
Tay-Sachs disease is a rare genetic disorder that presents significant challenges for patients and their families. […] This fact sheet provides an overview of the causes, symptoms, diagnosis, and treatment options for Tay-Sachs disease. […] The National Tay-Sachs Allied Diseases Association (NTSAD) provides a range of services including family support, genetic counseling, and education. […] The Cure Action for Tay-Sachs (CATS) Foundation is a UK-based charity dedicated to supporting families affected by Tay-Sachs and Sandhoff disease. […] The National Organization for Rare Disorders (NORD) offers resources specifically for Tay-Sachs disease through its Rare Disease Database. […] The Child Neurology Foundation (CNF) offers support for families affected by Tay-Sachs disease through various programs.
#38 Tay-Sachs Disease Services, Resources & Support: A Comprehensive Guide | Disability Resources
https://www.disabilityresources.org/tay.html
The National Tay-Sachs Allied Diseases Association (NTSAD) provides an extensive range of services for families and caregivers. […] The National Organization for Rare Disorders (NORD) offers a Caregiver Respite Program specifically designed to provide relief to those caring for a loved one with a rare disease like Tay-Sachs. […] The Nemours KidsHealth provides comprehensive support for parents of children diagnosed with Tay-Sachs disease. […] The Child Neurology Foundation (CNF) offers resources specifically for parents dealing with the neurological impacts of Tay-Sachs disease. […] The National Tay-Sachs Allied Diseases Association (NTSAD) offers extensive one-on-one support for families through their Family Services Team. […] The Cure Tay-Sachs Foundation offers support specifically for families dealing with late-onset Tay-Sachs (LOTS).
#39 First gene therapy for Tay-Sachs disease successfully given to two children
https://theconversation.com/first-gene-therapy-for-tay-sachs-disease-successfully-given-to-two-children-176870
More testing is needed to confirm whether our treatment can fully stop disease progression. Given that this was the first time our treatment was given to humans, we used a conservative dose below the maximum therapeutic effects we saw in our animal studies. My colleagues and I are currently conducting a follow-up clinical trial to test the safety and efficacy of increasing doses in a larger number of patients.